A mechanistic study found that saxagliptin, a DPP-IV inhibitor approved for T2D, increased the nuclear and cytoplasmic accumulation of the nuclear factor erythroid 2-related factor 2 (NRF2), which is a transcription factor involved in the regulation of oxidative stress, cell migration, and invasion. This evidence concerns the gene NFE2L2 and type 2 diabetes mellitus.